Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07287826 · ClinicalTrials.gov registry record · Phase 4
Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy
A Phase 4 study, sponsored by Woman's.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
NCT07287826: Recruiting Phase 4 study, sponsored by Woman's.
NCT07287826 is a Phase 4 study that is actively recruiting participants, run by Woman's. The registered enrollment target is 45 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07287826, a Phase 4 study, is actively recruiting participants, sponsored by Woman's.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a steroid mouthwash (dexamethasone) can prevent mouth sores caused by chemotherapy in adults with cancer. The main questions it aims to answer are: Does using dexamethasone mouthwash before and during chemotherapy lower the chance of getting moderate to severe mouth sores? Can this approach reduce pain and improve comfort during chemotherapy? Researchers will compare patients using the mouthwash to a historical group of patients who received similar chemotherapy but did not use the mouthwash, to see if the mouthwash helps prevent mouth sores. Participants will: Use a steroid mouthwash (4 times daily) for up to 8 weeks during chemotherapy Complete a short weekly survey about mouth discomfort during infusion visits
Primary Outcome
Proportion of participants who develop grade 2 or higher oral mucositis, as assessed by Common Terminology Criteria for Adverse Events (CTCAE v5.0), during chemotherapy treatment while using dexamethasone mouthwash.
Interventions
- DRUG Dexamethasone Mouthwash
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-04-02 |
| Est. Completion | 2028-01 |
| Phase | Phase 4 |
What NCT07287826 shows while recruiting
NCT07287826 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Dexamethasone Mouthwash is the first listed.
NCT07287826 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07287826 about?
NCT07287826 is a clinical study titled "Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy". The goal of this clinical trial is to learn if a steroid mouthwash (dexamethasone) can prevent mouth sores caused by chemotherapy in adults with cancer. The main questions it aims to answer are: Does using dexamethasone mouthwash before and during chemotherapy lower the chance of getting moderate t...
What is the current status of trial NCT07287826?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2026-04-02. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07287826?
The interventions under investigation include: Dexamethasone Mouthwash (DRUG).
Who is sponsoring clinical trial NCT07287826?
This trial is sponsored by Woman's, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07287826's enrollment target sits among peer trials
45 1354th of 2000 higher than 638 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI